Raschi E.; La Placa M.; Poluzzi E.; De Ponti F., The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice, «BRITISH JOURNAL OF DERMATOLOGY», 2021, 184, pp. 581 - 583 [Scientific article]Open Access
Raschi, Emanuel; Fusaroli, Michele; Ardizzoni, Andrea; Poluzzi, Elisabetta; De Ponti, Fabrizio, Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System, «CANCERS», 2021, 13, Article number: 1758 , pp. 1 - 12 [Scientific article]Open Access
Gatti M.; Bianchin M.; Raschi E.; De Ponti F., Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review, «EUROPEAN JOURNAL OF INTERNAL MEDICINE», 2020, 75, pp. 60 - 70 [Scientific article]
Raschi E.; Caraceni P.; Poluzzi E.; De Ponti F., Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?, «EXPERT OPINION ON DRUG SAFETY», 2020, 19, pp. 1367 - 1369 [Comment or similar]
Capelli, Irene; Vitali, Francesca; Zappulo, Fulvia; Martini, Silvia; Donadei, Chiara; Cappuccilli, Maria; Leonardi, Luca; Girardi, Anna; Aiello, Valeria; Galletti, Silvia; Faldella, Giacomo; Poluzzi, Elisabetta; DE Ponti, Fabrizio; LA MANNA, Gaetano, Biomarkers of Kidney Injury in Very-low-birth-weight Preterm Infants: Influence of Maternal and Neonatal Factors, «IN VIVO», 2020, 34, pp. 1333 - 1339 [Scientific article]Open Access
Raschi E.; Gatti M.; Gelsomino F.; Ardizzoni A.; Poluzzi E.; De Ponti F., Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance, «TARGETED ONCOLOGY», 2020, 15, pp. 449 - 466 [Scientific article]Open Access
Gatti M.; Poluzzi E.; De Ponti F.; Raschi E., Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis, «DRUG SAFETY», 2020, 43, pp. 1277 - 1285 [Scientific article]Open Access
Antonazzo I.C.; Poluzzi E.; Forcesi E.; Salvo F.; Pariente A.; Marchesini G.; De Ponti F.; Raschi E., Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system, «ACTA DIABETOLOGICA», 2020, 57, pp. 71 - 80 [Scientific article]
Raschi E.; Poluzzi E.; De Ponti F., Reduced neuropsychiatric events as “beneficial reactions” to drugs: Seek associations with caution, «BRAIN BEHAVIOR AND IMMUNITY», 2020, 84, pp. 275 - 276 [Comment or similar]
Raschi E, Salvo F, La Placa M, Poluzzi E, De Ponti F, Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction., «JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY», 2020, 34, pp. 430e - 431e [Scientific article]
Gatti M.; Ippoliti I.; Poluzzi E.; Antonazzo I.C.; Moro P.A.; Moretti U.; Menniti-Ippolito F.; Mazzanti G.; De Ponti F.; Raschi E., Reply-Letter to the editor - The valuable support of spontaneous reporting systems in exploring safety profile of dietary supplements, «CLINICAL NUTRITION», 2020, 39, pp. 3854 - 3855 [Comment or similar]
Swart, Floor; Bianchi, Giampaolo; Lenzi, Jacopo; Iommi, Marica; Maestri, Lorenzo; Raschi, Emanuel; Zoli, Marco; Ponti, Fabrizio De; Poluzzi, Elisabetta, Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database, «AGING», 2020, 12, pp. 19711 - 19739 [Scientific article]Open Access
Antonazzo I.C.; Poluzzi E.; Forcesi E.; Salvo F.; Pariente A.; Marchesini G.; De Ponti F.; Raschi E., Signal of potentially protective drug–drug interactions from spontaneous reporting systems: proceed with caution, «ACTA DIABETOLOGICA», 2020, 57, pp. 115 - 116 [Comment or similar]
Raschi E.; Bianchin M.; Gatti M.; Squizzato A.; De Ponti F., Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews, «DRUG SAFETY», 2019, 42, pp. 1409 - 1422 [Scientific article]
Raschi, E.; Poluzzi, E.; Marchesini, G.; De Ponti, F., Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?, «EXPERT OPINION ON PHARMACOTHERAPY», 2019, 20, pp. 1087 - 1090 [Scientific article]Open Access